Exercise capacity and outlook in cardiac amyloidosis
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at how well people with cardiac amyloidosis can exercise and how that might relate to their long-term health. You'll do a supervised bike or treadmill test while your heart and lungs are monitored.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You need a confirmed diagnosis of cardiac amyloidosis (from an MRI or heart scan).
- You must be able to do an exercise test on a bike or treadmill.
- You must not have severe lung disease that makes exercise difficult.
- You must not have chest pain during exercise that could be dangerous.
- You must not have other health problems that would keep you from safely exercising.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a 12-week supervised exercise program is safe and helpful for people with cardiac amyloidosis and heart failure. It aims to see if regular exercise can improve how you feel and function.
This study tests whether a supervised exercise and rehabilitation program can help people with a specific type of heart amyloidosis (ATTRwt) feel better and improve their heart function. It may be a good fit if you have stable heart failure and can safely exercise.
This study measures how well the heart’s tiny blood vessels work in people with cardiac amyloidosis, using special heart testing. It may help doctors understand the disease better and improve how patients are evaluated over time.
This study looks at how cardiac amyloidosis shows up on heart imaging, especially ultrasound (echocardiography). It may help doctors better describe and track the condition using your exam and test results.
This trial aims to better diagnose cardiac amyloidosis — a condition where abnormal proteins build up in the heart — by testing whether certain warning signs (called 'red flags') can help identify it. If you have any of these signs, the study will use heart scans to confirm the diagnosis.
This study uses two types of imaging (PET/CT and MRI) to see if they can better predict outcomes for people with AL cardiac amyloidosis. The goal is to improve how doctors understand and manage the disease.
Hear when a new Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.